Representatives Mikie Sherill (D-N.J.), Mike Levin (D-Calif.), and Abigail Spanberger (D-Va.) Oct. 11 introduced the Biomedical Innovation Expansion Act (H.R. 4667), which seeks to increase and extend funding for specific medical research projects at the National Institutes of Health (NIH).
The legislation would extend research programs funded through the NIH Innovation Account for four additional years through fiscal year (FY) 2030. The NIH Innovation Account was created in the 21st Century Cures Act (P.L. 114-255) [see Washington Highlights, Dec. 2, 2016] and established research programs under four specific initiatives.
The legislation would provide for a total of $10 billion in funding over 10 years beginning in FY 2021 for the four established research programs, as well as two new initiatives. The Innovation Account research projects would receive nearly $3 billion for the All of Us research program, $2.9 billion for the Brain Research through Advancing Innovative Neuroethologies (BRAIN) Initiative, $1.5 billion for the Cancer Moonshot Initiative, and $220 million for regenerative medicine.
The bill would also provide new funding for research into antimicrobial resistance and antibiotic resistant bacteria ($1.6 billion) and research activities related to rare diseases ($758 million) over 10 years, also beginning in FY 2021.
Separately, Rep. Anna Eshoo (D-Calif.) and Rep. Scott Peters (D-Calif.) introduced the Investing in Safety and Innovation Act of 2019 (H.R. 4633), which would extend funding for innovation projects at the Food and Drug Administration (FDA) established in the 21st Century Cures Act.